^(188)Re标记物治疗肝细胞性肝癌的研究进展  

Rhenium -188 based radiopharmaceuticals for the treatment of hepatocellular carcinomas:its recent progress in research

作　　者：李依明 王杰 程旭[2] 曹莉明 

机构地区：[1]南京医科大学第一附属医院放射介入科,南京210029 [2]南京医科大学第一附属医院核医学科,南京210029

出　　处：《介入放射学杂志》2012年第7期611-613,共3页Journal of Interventional Radiology

摘　　要：近年来,^(188)Re标记的放射性药物成为治疗肝细胞性肝癌的讨论热点之一。逐渐增多的研究表明其治疗肝细胞性肝癌具有安全性和有效性,是一种有前景治疗用放射性核素。本文就^(188)Re物理特性及其标记物在治疗肝细胞性肝癌的动物实验研究、临床研究及放射性防护等方面的新进展进行总结。For recent years, the discussion about the rhenium-188 based radiopharmaceuticals has become a hot subject concerning the treatment of hepatocellular carcinomas （HCCs）. Numerous researches have indicated that rhenium-188 based radiopharmaceuticals can be safely and effectively employed in the treatment of HCCs. This paper aims to introduee the physical properties of Rhenium-188 and to summarize the recent research progress in treating inoperable HCCs with Rhenium-188, both in clinical and experimental studies, as well as in the radioactive prevention.

关 键 词：铼-188 肝细胞性肝癌 核素 

分 类 号：R735.7[医药卫生—肿瘤]